Target family: C1: Papain (type: enzyme)
Target: cathepsin S

Ligand: compound 4d [PMID: 38746883] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.149999618530273 pIC50
Reference (Journal): Identification of Dual Inhibitors Targeting Main Protease (M<sup>pro</sup>) and Cathepsin L as Potential Anti-SARS-CoV-2 Agents.
Published in: ACS Med Chem Lett

Ligand: compound (R)-26 [PMID: 22686657] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.3 pKi
Reference (Journal): Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F.
Published in: J Med Chem

Ligand: K777 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKi
Reference (Journal): A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.
Published in: ACS Chem Biol

Ligand: LHVS (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
Published in: J Biol Chem

Ligand: odanacatib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.21999979019165 pIC50
Reference (Journal): The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Published in: Bioorg Med Chem Lett

Ligand: petesicatib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.520000457763672 pIC50
Reference (Journal): Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury.
Published in: Sci Rep

Ligand: petesicatib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 10 pIC50
Reference (Journal): Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury.
Published in: Sci Rep

Ligand: VBY-825 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.890000343322754 pKi
Reference (Journal): Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.
Published in: Biochimie

Ligand: VBY-825 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.399999618530273 pKi
Reference (Journal): Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.
Published in: Biochimie

Ligand: VBY-825 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.109999656677246 pKi
Reference (Journal): Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.
Published in: Biochimie